International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): International normalized ratio (INR) =< 3 (to be done/tested only for subjects on warfarin)
Patients receiving anticoagulation treatment are allowed to participate with international normalized ratio (INR) established within the therapeutic range
Subjects taking warfarin should be monitored regularly for changes in prothrombin time or international normalized ratio (INR)
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
Obtained within 14 days prior to treatment start: International normalized ratio (INR) =< 1.5
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) less than or equal to 1.5
Within 10 days of treatment initiation: Institutional normalized ratio (INR) =< 1.5 X institutional upper limit of normal (IULN)
International normalized ratio (INR) < 1.1 x institutional upper limit of normal
Coagulation: International Normalized Ratio (INR) < 1.5 times normal, activated Partial Thromboplastin Time (aPTT) < 1.5 times normal. Patients receiving therapeutic doses of anticoagulant therapy may be considered eligible for the trial if INR and aPTT are within the acceptable therapeutic limits for the institution.
International normalized ratio (INR) =< 1.2 times ULN; subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
International normalized ratio (INR) =< 1.2 X upper limit of normal (ULN)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation); (to be eligible, prothrombin time/international normalized ratio [PT INR] should be < 1.4 for patients not on warfarin)
Obtained =< 21 days prior to registration: International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN; NOTE: This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.2
International normalized ratio of < 1.5
International normalized ratio (INR)/PTT =< 2 times normal; timeline: within 3 weeks prior to enrollment
Blood coagulation parameters: international normalized ration (INR) =< 1.5
International normalized ratio (INR) < 1.5; partial thromboplastin time (PTT) < 1.5 upper limit of normal (ULN); d-dimer < 250ng/mL
International normalized ratio (INR) ? 1.5 × ULN (? 2.5 × ULN if on anticoagulants)
International normalized ratio (INR) =< 1.5
Adequate coagulation tests: international normalized ratio ?1.5
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) less than or equal to 1.5
International normalized ratio (INR) = 1.7
International normalized ratio (INR) =< 1.5 unless on direct thrombin inhibitor at time of study entry
INR > 1.3
International normalized ratio (INR) =< 2
Has adequate blood clotting function, defined as: International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN.
International normalized ratio (INR) =< 1.5 and partial thromboplastin time (PPT) =< 5 seconds above the upper limit of normal (ULN)
INR < 1.3 (or < 3 on anticoagulants)
Coagulation: International normalized ratio (INR) ?1.2 within 28 days of starting study.
Prothrombin time (PT)-international normalized ratio (INR) =< 1.5 x institutional ULN (for participants on anticoagulation therapy, =< 1.5 x their baseline value)
International normalized ratio (INR) ?1.5;
Adequate blood coagulation function defined by International Normalized Ratio (INR) ?1.5 (except for participants on warfarin therapy where INR must be ?3.0 prior to randomization)
International normalized ratio (INR) =< 1.5
Obtained =< 2 weeks prior to registration: International normalized ratio (INR) =< 1.5 ULN
Prothrombin time (PT)-international normalized ratio (INR) =< 1.5 x institutional ULN (for participants on anticoagulation therapy, =< 1.5 x their baseline value)
International normalized ratio =< 1.5
INR < 1.5 × ULN
International normalized ratio (INR) =< 1.5
International Normalized Ratio (INR) for coagulation above upper normal range
For participants not receiving therapeutic anticoagulation: International normalized ratio (INR) or activated partial thromboplastin time (aPTT) less than or equal to (</=) 1.5*upper limit of normal (ULN) within 28 days prior to initiation of study treatment
International normalized ratio (INR) ? 2 × ULN
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) or prothrombin time (PT) INR ?1.5 × institutional ULN or PT ?5 seconds above institutional ULN
International Normalized Ratio (INR) < 1.5 (except if patient is on oral anticoagulation therapy).
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) < 1.5 x ULN (for patients on anticoagulation they must be receiving a stable dose for at least 1 week prior to enrollment)
INR ?1.5× ULN
International normalized ratio/prothrombin time ? 1.5 x upper limit or normal
International normalized ratio (INR)/ partial thromboplastin time (PTT) =< 1.5 x ULN; (subjects who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care
Transaminases ? 2 times above the upper limits of the institutional normal, - INR<2 (international normalized ratio) if off of anticoagulation. Patients on anticoagulation therapy with an INR>2 may be enrolled at the discretion of the investigator if they have not had any episodes of severe hemorrhage and if the site to be injected is not located in the oropharynx or another area where achieving homeostasis would be complicated by local anatomy.
International normalized ratio (INR)/partial thromboplastin time (PTT) has to be =< 1.5 x ULN
Prothrombin time international normalized ratio (INR) =< 2
Must have an international normalized ratio (INR) < 1.5
International normalized ratio (INR) =< 1.5
International normalization ratio (INR) and activated partial thromboplastin time (aPTT) < 1.2 x ULN
International Normalized Ratio (INR) > 1.5
Normal coagulation defined as normal International Normalized Ratio (INR) or per institutional guidelines.
International normalized ratio (INR) < 1.5.
International normalized ratio (INR) =< 1.7
International normalized ratio (INR) < 2.0.
Prothrombin (PT) - international normalized ratio (INR) < 1.5
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 X ULN, obtained =< 14 days prior to registration
International normalized ratio (INR) less than 1. 5 X ULN
International normalized ratio (INR) < 1.5.
International normalized ratio (INR) < 1.3
International normalized ratio (INR) < 1.3
Within 28 days prior to administration of study treatment: Coagulation parameters (international normalized ratio [INR] and activated partial thromboplastin time [aPTT]) within 1.25 x ULN institutional limits, except where a lupus anti-coagulant has been confirmed, or except patients on anticoagulation
International normal ratio (INR) < 1.3 or ? institutional ULN (or ? 3.0 if on therapeutic anticoagulation)
Patients on therapeutic anti-coagulation are eligible if there is no bleeding and they are on a stable dose of anti-coagulation therapy (e.g., on coumadin with an international normalized ratio [INR] of 2 to 3) for at least 7 days before registration (prior to the start of therapy)
International normalized ratio > 1.5
Institutional normalized ratio (INR) and partial thromboplastin time (aPTT) < 1.5 x ULN
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN if not on therapeutic anticoagulation; patients receiving therapeutic anticoagulation will be allowed if maintained on a stable dose within 14 days of study registration
Patients who have an international normalized ratio (INR) or platelet count which are not correctable to < 1.8 and > 35,000 respectively
INR ? 1.5
Obtained with 21 days of registration: international normalized ratio =< 2.3
INR < 1.5 × ULN
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x institutional upper limit of normal (or an in-range INR, usually between 2 and 3 if a patient is on a stable dose of therapeutic warfarin)
Institutional normalized ratio (INR) and partial thromboplastin time (aPTT) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5 X institutional upper limit of normal (ULN) for patients not receiving therapeutic anticoagulation (unless dysfunction is secondary to lymphoma involvement)
International normalized ratio (INR) < 2, at the time of enrollment; subjects on anticoagulation (such as coumadin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigator
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN; this applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) > 1.5 x upper limit of normal (ULN) \r\n* This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN for patients who do not receive therapeutic anticoagulation
International normalized ratio (INR) from 0.8 to 1.2
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN within 7 days prior to study enrollment
Within 14 days of the first study treatment: International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (for patients on anticoagulation they must be receiving a stable dose for at least 1 week prior to randomization)
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ?1.5
International normalized ratio (INR) =< 1.5 (except for patients who are on full-dose warfarin)
International normalized ratio (INR) < 1.5
International normalized ratio (INR) and partial thromboplastin time (PTT) < 1.5 x ULN
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN
International normalized ratio (INR) and activated partial thromboplastin time (PTT) < 1.5 x upper limit of normal (ULN) provided the patient is not on anticoagulation therapy
INR ? 1.5 x ULN;
(For both cohorts A and B): International normalized ratio (INR) =< 2
International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN; unless patient is on therapeutic anticoagulation
PT (Prothrombin time) and/or international normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5 obtained < 4 weeks prior to starting treatment
International normalized ratio (INR) =< 1.5
International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN; (subjects who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists)
International Normalized Ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5 x ULN
Serum coagulation studies (international normalized ratio [INR]/partial thromboplastin time [PTT]) and platelet counts suitable for surgery per surgeon discretion
If subject is receiving Coumadin (warfarin), a stable international normalization ratio (INR) of 2-3 is required.
International normalized ratio (INR) =< 1.5
Prothrombin time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN)
International normalized ration (INR) within 1.25 x ULN institutional limits, except where a lupus anti-coagulant has been confirmed
Obtained =< 14 days prior to registration: Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 X ULN
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
Partial thromboplastin time (PTT) must be =< 1.5 x upper normal limit of institution's normal range and INR (international normalized ratio) < 1.5; subjects on anticoagulant (such as warfarin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigator
Prothrombin time/international normalized ratio (PT INR) < 1.4
International normalization ratio (INR) < 1.5 times ULN, or if on warfarin, can safely transition off for biopsy
International normalization ratio (INR) < 1.5 times ULN, or if on warfarin, can safely transition off for biopsy
INR ?1.5
International normalized ratio (INR) =< 1.7
Impaired coagulation as evidenced by:\r\n* International normalized ratio (INR) > 1.5 times ULN, or\r\n* Activated partial thromboplastin time (aPTT) > 1.5 times ULN
Obtained within 14 days prior to registration; international normalized ratio (INR) ? 2
INR > 2
Prothrombin time (PT) and international normalized ratio (INR) =< 1.5 x ULN
Completed within 60 days of surgery: International normalized ratio INR ? 1.5 in patients not utilizing systemic anticoagulation as part of their medical regimen
Prothrombin time with international normalized ratio (INR) =< ULN for the laboratory
International normalized ratio (INR) =< 2.0 or correctable to 2.0 with vitamin K therapy
International normalized ratio (INR) > 1.5 INR
International normalized ratio (INR) =< 1.2
International normalized ratio (INR) < 1.5 x ULN
International normalized ratio (INR) < IULN or prothrombin time (PT) < IULN
International normalized ratio (INR) >= 1.7
International normalized ratio (INR) < 2 if off of anti-coagulation; patients on anti-coagulation therapy with an INR > 2 may be enrolled at the discretion of the investigator if they have not had any episodes of severe hemorrhage
For patients undergoing serial tumor biopsies, international normalized ratio (INR) and activated partial thromboplastin time (PTT) must be within 1.5 X the upper limit of normal
Obtained =< 14 days prior to registration: International normalized ratio (INR) =< 2.0
International normalized ratio (INR) =< IULN or prothrombin time (PT) =< IULN
International normalized ratio (INR) < 1.5
International normalized ratio (INR) < 1.5
International normalized ratio (INR) =< 2
Prothrombin time/international normalized ratio (PT/INR) < 1.4 for patients not on warfarin
Therapeutic anticoagulation with international normalized ratio (INR) modifying drug of or use of antiplatelet therapy (with the exception of low dose aspirin < 325mg/d)
International normalized ratio (INR) =< 1.5 unless on warfarin in which case INR < 3.0 is acceptable
REGORAFENIB INCLUSION CRITERIA: International normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x ULN (patients who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate, provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is predose as defined by the local standard of care)
Subjects must have adequate blood clotting function, defined as international normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN
International Normalized Ratio (INR) > 1.5 ULN or activated partial thromboplastin time (aPTT) > 1.5 ULN. Subject is currently receiving or intending to receive anti-coagulants for therapeutic purposes. Prophylactic use of anticoagulants is allowed.
International normalized ration (INR) =< 1.5
The patient must have adequate coagulation function as defined by international normalized ratio (INR) =< 1.5 and
International normalized ratio (INR) =< 2
INR >= 2
International normalized ratio (INR) =< 2.0
International normalized ratio (INR) =< 1.5 x institutional ULN
Prothrombin time or international normalized ratio (INR) =< 1.5 X upper limit of normal (ULN)
Prothrombin time (PT)/international normalized ratio (INR) < 1.7 unless using warfarin for therapeutic anti-coagulation
International normalized ratio (INR) < 1.5, except for subjects receiving warfarin therapy; for subjects who are receiving warfarin for prophylaxis or treatment of thrombosis, INR values should be carefully monitored while patients are on study
International normalized ratio (INR) is =< 1.5
International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 2
International normalized ratio (INR) from 0.8 to 1.2
Prothrombin time (PT) and international normalized ratio (INR) < 1.2 x ULN
Coagulopathy international normalized ratio (INR) > 1.5
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (for patients on anticoagulation they must be receiving a stable dose for at least 1 week prior to randomization)
Known, existing uncontrolled coagulopathy, international normalized ratio (INR) > 1.5
International normalized ratio (INR) =< 1.5
INR and APTT ? 1.5 x ULN.
Are unsuitable for endoscopy (either because of hemodynamic instability, respiratory distress or unsafe hematological parameters such as refractory anemia < 7 g/dL, thrombocytopenia < 50 K/mcL, or coagulopathy with international normalized ratio [INR] > 2.0)
Known coagulopathy/thrombocytopenia (international normalized ratio [INR] > 1.5, platelets < 75)
Has adequate blood clotting function, defined as: - International normalized ratio and activated partial thromboplastin time =<1.5 XULN
International normalized ratio (INR) < 2.0
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN (except for patients on anticoagulation)
International normalized ratio or INR must be =< 1.5 unless on therapeutic blood thinners
International normalized ratio (INR) < 1.3
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x institutional upper limit of normal (IULN)
Requirement for anticoagulation treatment that increases international normalized ratio (INR) or activated partial thromboplastin time (aPTT) above the normal range (low dose deep vein thrombosis (DVT) or line prophylaxis is allowed).
“International normalized ratio” or INR must be =< 1.5
Patients on anticoagulant therapy with unstable dose of warfarin and/or having an out-of- therapeutic range international normalized ratio (INR) (> 3) within the 4 weeks prior to drug administration
International normalized ratio (INR) or prothrombin time (PT) < 1.5 x ULN
International normalized ratio (INR) =< 1.8
International normalized ratio (INR) =< 2
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless the patient is receiving anticoagulant therapy
International normalized ratio (INR) < 1.3 x ULN
International normalized ratio (INR) value greater than 1.5
An international normalized ratio (INR) =< 1.5 (patients who are therapeutically anticoagulated for unrelated medical conditions such as atrial fibrillation and whose antithrombotic treatment can be withheld for operation will be eligible)
International normalized ratio (INR) =< 2
International normalized ratio (INR) < 2.0
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) < 2
International normalized ratio =< 1.5 and activated prothrombin time =< 1.5 x ULN within 7 days prior to enrollment; the use of full-dose oral or parenteral anticoagulants is permitted as long as the international normalized ratio (INR) or activated partial thromboplastin time (aPTT) is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least two weeks prior to the first study treatment
Normal blood coagulation as evidenced by partial thromboplastin time (PTT) < 1.5 IULN and international normalized ratio (INR) < 1.5
International normalized ratio or INR must be =< 1.5 unless on therapeutic blood thinners
Prothrombin time (PT)/international normalized ratio (INR) =< 1.2 x ULN
All patients should have normal coagulation, with international normalized ratio (INR) < 1.3 and able to withhold anti-coagulation medications a minimum of 24 hours prior to radiosurgery (or until INR normalizes), on the day of treatment and 24 hours after radiosurgery has concluded; those patients getting WBRT may continue these medications
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x upper limit of normal (ULN); subjects receiving anticoagulation therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
International normalized ratio (INR) < 2; subjects on anticoagulant (such as coumadin) must have an international normalized ratio (INR) < 5
Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate; for patients on warfarin, the international normalized ratio (INR) should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable
International normalized ratio (INR) < 2.0
Evidence of a bleeding diathesis, coagulopathy or prothrombin time (PT) international normalized ratio (INR) > 1.5
International normalized ratio (INR) must be =< 2.3
International normalized ratio (INR)/prothrombin time (PT) =< 1.5 obtained =< 14 days prior to registration
International Normalized Ratio (INR) or PT/aPTT <1.5 x ULN. For subjects receiving anticoagulation therapy, PT/aPTT and INR should not be greater than the recommended range for the intended use of the anticoagulant
Patients must have adequate coagulation (international normalized ratio [INR] ? 1.5, activated partial thromboplastin time [aPTT] ?1.5 X the upper limit of normal [ULN])
International normalized ratio (INR) =< 1.7
Adequate coagulation: international normalised ratio (INR) ?1.5 for patients on anti-coagulation therapy
International normalized ratio (INR) < 1.3 (or < 3 if on warfarin or other anticoagulants) during screening evaluation
Coagulation: Prothrombin Time (PT) > 4 seconds more than the ULN or International Normalized Ratio (INR) > 1.7
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x ULN; NOTE: subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
Patients should have normal coagulation [International Normalized Ratio (INR) < 1.3] and be able to withhold anticoagulation/antiplatelet medications a minimum of 24 hours prior to radiosurgery treatment (or until INR normalizes), on the day of treatment and 24 hours after radiosurgery treatment has concluded.
International normalized ratio (INR) > 2.0
International normalized ratio (INR) =< 2
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN within 14 days prior to randomization; for laboratories that do not report an ULN for the INR assay, use =< 1.5 as the value for the ULN; patients receiving therapeutic anti-coagulants are not eligible
PT/international normalized ratio (INR) ?ULN; aPTT ?ULN.
International normalized ratio (INR) =< 1.5 x upper limit of normal (ULN)
International normalized ration (INR) < 1.5
International normalization ratio (INR) or prothrombin time (PT) ? 1.5 x
International normalized ratio (INR) ? 2 (If coagulopathy is related to disease, this criterion does not apply) within 14 days prior to registration
Within 14 days prior to first dose of study drug treatment: International normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5 =< 14 days prior to registration
Partial thromboplastin time (PTT) must be =< 1.5 X upper normal limit of institution's normal range and INR (international normalized ratio) =< 1.5; subjects on anticoagulant (such as coumadin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigator; alternate anticoagulation should be considered
International normalized ratio or INR must be ? 1.5 unless on therapeutic blood thinners ? 2 weeks
Serum prothrombin time, international normalized ratio (INR) and partial thromboplastin times which fall within normal limits or levels outside the normal range determined not to be clinically significant by the PI
International normalized ratio =< 1.5 and activated prothrombin time =< 1.5 x ULN for patients not receiving anti?coagulation therapy
The use of full?dose oral or parenteral anticoagulants is permitted as long as the international normalized ratio (INR) or activated partial thromboplastin time (aPTT) is within therapeutic limits (according to the medical standard of the enrolling institution), and the patient has been on a stable dose of anticoagulants for at least two weeks prior to the first study treatment
International normalized ratio (INR) =< 1.5
International normalized ratio (INR)/ partial thromboplastin time (PTT) < 1.5 x ULN; (subjects who are treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring [day 5 of cycle 1 and day 1 of each cycle] is mandatory) will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care)
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.4
Within 14 days prior to registration: International normalized ratio (INR) < 2.0
Prothrombin time (PT)/international normalized ratio (INR) within normal limits (+/- 15%) or within therapeutic range if on warfarin
International normalized ratio of prothrombin time (INR) within 28 days before randomization must be =< ULN for the lab; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history
Performed within 14 days prior to study: International normalized ratio (INR) < 2 if off of anticoagulation; patients on anticoagulation therapy with an INR > 2 may be enrolled at the discretion of the investigator if they have not had any episodes of severe hemorrhage
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5
ARM A: obtained =< 14 days prior to registration: \r\n* International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 1.4 unless receiving therapeutic doses of coumadin
Obtained within 30 days prior to registration: International normalized ratio (INR) or prothrombin time (PT) =< 2 x ULN (Note: use of vitamin K antagonist is not allowed)
Cohort 2 (MTD) only: prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 2
International normalization ratio (INR) =< 2.0 mg/dL
Prothrombin time (PT)/international normalized ratio (INR) within institutional normal limits
Prothrombin time (PT)/international normalized ratio (INR) < 1.25 x ULN (Cohort II [MTD] only)
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) < 1.3 (or < 3 if on warfarin or other anticoagulants)
INR > 2.5
International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN; (patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care)
International normalized ratio (INR) < 1.5; subjects on anticoagulant (such as Coumadin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigator
International normalized ratio (INR): < 1.5 x institutional upper limit of normal OR < 3 if on warfarin or other anticoagulants; there should be no evidence of active bleeding while on anticoagulants
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5
INR =< 1.5
International normalized ratio (INR) =< 1.5
Within 14 days of subject registration: International normalized ratio (INR) =< 1.5
International normalized ratio =< 1.3 (or =< 3 on anticoagulants)
International normalized ratio (INR) =< 1.5 x ULN or prothrombin time (PT) =< 1.5 x ULN seconds above control unless patient is currently receiving warfarin therapy for the treatment or prevention of venous thrombosis
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.2
International normalized ratio (INR) =< 1.5 X ULN (if not on anticoagulation)
International normalized ratio (INR) < 1.5 (or < 3 if on warfarin or other anticoagulants)
Prothrombin time (PT), international normalized ratio (INR) less than 1.5 times the institutional upper limit of normal
International normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x ULN
Prothrombin time (PT)/international normalized ratio (INR) monitoring, < 1.5 x institutional upper limits of normal
Prothrombin time (PT)/international normalized ratio (INR) must be =< 1.2 x the laboratory ULN
Prothrombin time (PT) within 2 seconds of the upper limit of normal (international normalized ratio [INR] =< 1.8)
International normalized ratio (INR) =< 1.5 and activated partial thromboplastin time (aPTT) within 1.1 x ULN; patients on warfarin therapy are not eligible due to the requirement for multiple biopsies
International normalized ratio (INR) =< 1.5
International normalized ratio or INR must be < 1.5
International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 1.5 x institutional ULN
International normalized ratio (INR) =< 2.0
Adequate coagulation defined as\r\n* International normalized ratio (INR)/prothrombin time (PT) =< 1.5 x upper limit of normal
Prothrombin time (PT) =< 26 seconds or international normalized ratio (INR) =< 2.5
International normalized ratio ?1.5 × ULN and partial thromboplastin time ?5 seconds above ULN.
Inadequate liver or renal function; Intracranial bleeds or invasive malignancy over the previous 2 years - international normalized ratio (INR) laboratory values cannot be > 1.5 x upper limit of normal at study entry.
International normalized ratio (INR) =< 1.5
Performed within 14 days of patient registration: International normalized ration (INR) =< 1.5
Only for patients who test positive for hepatitis B virus or hepatitis C virus: partial thromboplastin time (PTT)/international normalized ratio (INR) =< ULN (institutional)
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x institutional upper limit of normal (IULN) (if not receiving anticoagulation therapy)
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ? 1.5.
Coagulation: International Normalized Ratio (INR) ? 1.2
International normalized ratio (INR) =< 2, obtained =< 21 days prior to registration
International normalized ratio of prothrombin time must be less than or equal to 1.5 times the ULN. Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no underlying abnormality in coagulation parameters exists per medical history.
INR < 2.0
For patients not receiving therapeutic anticoagulation: international normalized ratio (INR) or activated partial thromboplastin time (aPTT) =< 1.5 x ULN, obtained within 14 days prior to initiation of study treatment
Coagulation: International Normalized Ratio (INR) ? 1.2
Individuals not receiving anticoagulant medication must have an international normalized ratio (INR) ? 1.5 and activated partial thromboplastin (aPTT) ? 1.5 x upper limit of normal (ULN)
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) less than or equal to 1.5.
Prothrombin Time - International Normalized Ratio (PT-INR)
International normalized ratio (INR)/ Partial thromboplastin time (PTT) ? 1.5 x ULN. (Subjects who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care.
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) > 1.5 x ULN, in subject who is not therapeutically anticoagulated.
International Normalized Ratio (INR) or Prothrombin Time (PT) ?1.5 X ULN
Subjects with coagulopathies, including thrombocytopenia with platelet count < 75,000, international normalized ratio (INR) > 1.5 and partial thromboplastin time > 50 sec
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) > 2
International normalized ratio (INR) < or equal to 1.5; patients receiving anti-coagulation treatment with an agent such as warfarin or heparin MAY be allowed to participate; for patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored weekly, or as defined by the local standard of care, until INR is stable
International normalized ratio (INR) > 1.5
International normalized ratio (INR) within normal limits (UIHC)
Adequate blood coagulation function, defined as international normalized ratio (INR) less than or equal to 2.3
Prothrombin time/international normalized ratio (PT INR) < 1.4 for patients not on warfarin confirmed by testing within 14 days prior to study registration
International normalized ratio (INR) < 1.5 x institutional ULN
International normalized ratio (INR) must be < 1.5
International normalized ratio (INR) =< 1.4 x ULN
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless on medication known to alter INR and/or aPTT
Within 14 days of enrollment: International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN if not on therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 2; factor 10A drawn if patient on anticoagulant Eliquis
International normalized ratio (INR) > 2 in the absence of anticoagulation therapy
International normalized ratio (INR) ? 1.5 and activated partial thromboplastin time (aPTT) ? 1.5 x the ULN.
International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5.
Within 14 days prior to registration: coagulation parameters (international normalized ratio [INR], activated partial thromboplastin time [aPTT]) =< 1.25 x institutional ULN
Prothrombin time international normalized ratio (INR) =< 2; AND
International normalized ratio (INR) > 2
International normalized ratio (INR) =< 1.5
International normalized ratio > 1.7
International normalized ratio (INR) < 1.5 times ULN
International normalized ratio 1.5 × ULN or prothrombin time 5 seconds above ULN.
International normalized ratio (INR) > 1.6 and a partial thromboplastin time (PTT) > 40 seconds
International normalized ratio (INR) < 2.0
International normalized ratio (INR) < 1.5 x ULN for institution unless patient is on planned therapy with anticoagulants (i.e., warfarin) with higher target planned obtained =< 14 days prior to registration; in those cases, INR up to 3.5 is acceptable
International normalized ratio (INR)/partial thromboplastin time (PTT) 1.5 x ULN; (subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care)
International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN (obtained =< 7 days prior to randomization)\r\n* NOTE: patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care
INR < 1.5 × ULN
Coagulation parameters (international normalized ratio [INR], activated partial thromboplastin time [aPTT]) =< 1.25 x ULN institutional limits, except where a lupus anti-coagulant has been confirmed
Prothrombin time (PT) such that international normalized ratio (INR) is less than or equal to 1.3 x upper limit of normal (ULN)
International normalized ratio (INR) =< 1.5
international normalized ratio (INR) must be within normal limits of the local laboratory ranges.
International normalized ratio (INR) =< 2
Adequate prothrombin time/international normalized ratio (PT/INR) < 1.4 for patients not on warfarin confirmed by testing within 21 days prior to study registration
International normalized ratio (INR) < 2
Patients must have normal coagulation studies (prothrombin time [PT]/international normalized ratio [INR] < 1.5 times ULN) within 14 days prior to the initiation of study treatment
International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN; Note-subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that their medication dose and INR/PTT are stable; close monitoring (day 1 of each cycle) is mandatory; if either of these values is above the therapeutic range, the doses should be modified and the assessments should be repeated weekly until they are stable
International normalized ratio (INR) =< 2
Prothrombin time (PT)/international normalized ratio (INR) < 1.5 times upper limit of normal within 14 days before enrollment
International normalized ratio (INR) less than or equal to 2
Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 times upper limit of normal (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin)
Adequate coagulation system defined as an international normalized ratio (INR) of less than 1.4 and a partial thromboplastin time (PTT) of less than 34
International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN; subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care
Adequate blood clotting time with an international normalized ratio (INR) < 2
International normalized ratio (INR) < 1.5 or a prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits; patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate; for patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable
International normalized ratio (INR) =< 2.0
Partial thromboplastin time (PTT) =< 60, international normalized ratio (INR) =< 1.5 institutional ULN unless on warfarin therapy (investigator would need to determine if safe for participant to stop warfarin prior to [optional] biopsy)
International normalized ratio (INR) > 2
International Normalized Ratio (INR) less than 1.5 within 8 weeks prior to initial cryoablation procedure.
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x upper limit of normal (ULN) (tested within 14 days prior to registration) \r\n* Subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
International normalized ratio (INR) =< 1.5 institutional ULN unless on warfarin therapy (investigator would need to determine if safe for participant to stop warfarin prior to biopsy)
International normalized ratio (INR) must be less than 1.5 in patients not on Coumadin therapy
Patients receiving anticoagulation treatment are allowed to participate with international normalized ratio (INR) established within the therapeutic range
International normalized ratio (INR) < 1.3 (or < 3 on anticoagulants)
International normalized ratio (INR) =< 1.2 X upper limit of normal (ULN); only required for patients receiving anticoagulant therapy; patients are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
International normalized ratio (INR) must be =< 1.5 unless on therapeutic blood thinners
International normalized ratio (INR) =< 2.0 (unless due to therapeutic warfarin use)
International normalized ratio or INR must be =< 1.5 unless on therapeutic blood thinners
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x upper limit of normal (ULN)
International normalized ratio (INR) =< 1.5
Concurrent treatment with warfarin (Coumadin) is allowed, but close monitoring of the prothrombin time (PT)/international normalized ratio (INR) is recommended
International normalized ratio (INR) < 1.5 x ULN
International normalized ratio (INR) =< 2.5
Obtained within 2 weeks from study entry: International normalized ratio (INR) =< 2
International normalized ratio (INR) >= 1.5
International normalized ratio (INR) =< 1.5 unless using warfarin for therapeutic anti-coagulation
International normalized ratio (INR) =< 1.2 x institutional upper limit of normal (IULN); patients receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.4
International normalized ratio (INR) > 1.5; (in patients receiving anticoagulants [such as warfarin] INR must be between 2.0 and 3.0 in two consecutive measurements 1-4 days apart)
International normalized ratio (INR) =< 1.5 and activated partial thromboplastin time (aPTT) within normal limits (WNL)
Elevated international normalized ratio (INR) (> 1.7)
International normalized ratio (INR) =< 1.2 X upper limit of normal (ULN); subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
Maximum Child-Pugh score of 5 (NOTE: this requires prothrombin time [PT] or international normalized ratio [INR] measurement at baseline)
Prothrombin time (PT) or international normalized ratio =< 1.2 X upper limit of normal (ULN); subjects receiving anticoagulant therapy are eligible if their international normalized ratio (INR) is within the recommended range for the desired level of anticoagulation
International normalized ratio (INR) =< 1.5; patients are eligible if elevated INR is due to anti-coagulation medications and will need to provide documentation of stable coagulation parameters prior to study entry
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5; subjects on anticoagulant (such as Coumadin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigator
Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for the management of venous thrombosis including pulmonary embolus)
International normalized ratio (INR) =< 1.5 x ULN
Patients on stable anticoagulation are eligible for enrollment; for patients on warfarin, prothrombin time (PT)/international normalized ratio (INR) should be monitored every 2 weeks during induction therapy, monthly thereafter, or more frequent as clinically indicated
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 X upper limit of normal (ULN); subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 X upper limit of normal (ULN)
International normalized ratio (INR) =< 1.5 patients receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
International normalized ratio (INR) =< 1.5 (anticoagulation is allowed if target INR =< 1.5 on a stable dose for > 2 weeks at time of study entry)
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x ULN
International normalized ratio (INR)/partial thromboplastin time (PTT) within 1.5 x upper limit of normal (Common Terminology Criteria for Adverse Events [CTCAE] 4.0 grade 1 abnormality is acceptable)
International normalized ratio (INR) =< 2
International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN\r\n* Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care
Prothrombin time (PT) or international normalized ratio (INR) =< 1.5 X institutional upper limit of normal (ULN) unless patients are on therapeutic anticoagulation with warfarin
EXPANSION COHORT ONLY: Prothrombin time (PT) or international normalized ratio (INR) =< 2 X institutional upper limit of normal (ULN) unless patients are on therapeutic anticoagulation with warfarin
International normalized ratio (INR) > 1.5 and activated partial thromboplastin time (aPTT) > 1.5 x the ULN (except for subjects receiving anticoagulation therapy) in the absence of therapeutic intent to anticoagulate the subject; therapeutic anticoagulation is permitted
International normalized ratio (INR) 0.8 to upper limit of normal (ULN) or ? 3 for subjects receiving anticoagulant therapy such as Coumadin or heparin
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless on medication known to alter INR and aPTT
INR < 1.5 × ULN
Coagulation parameters (international normalized ratio [INR], activated partial thromboplastin time [aPTT]) within 1.25 x upper limit of normal institutional limits, except where a Lupus anti-coagulant has been confirmed
International normalized ratio (INR) =< 1.7 (if not due to anticoagulants)
Prothrombin time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) unless receiving therapeutic anticoagulation
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5 and partial thromboplastin time (PTT) within normal limits; (patients who are on therapeutic anticoagulation with warfarin should have documentation of INR =< 1.5 or PTT within normal limits prior to initiating that therapy)
International normalized ratio (INR) =< 1.4 x ULN at the time of registration
Platelet count <50,000/mm3 or international normalized ratio >1.5.
International Normalized Ratio of at least 1.7 Adequate hepatic function including:
Partial thromboplastin time (PTT) must be =< 2 X upper normal limit of institution's normal range and INR (international normalized ratio) < 2; subjects on anticoagulant (such as Coumadin) must have a PTT =< 5 X upper normal limit of institution's normal range and INR (international normalized ratio) < 5
INR and aPTT within 1.5 ULN
International normalized ratio (INR) =< 2
International normalized ratio (INR)/ partial thromboplastin time (PTT) =< 1.5 x ULN
International normalized ratio (INR) =< 2
International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN (subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care)
International normalized ratio (INR) ? 1.5 x ULN
International normalized ratio (INR) ? 1.5 x ULN
International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN; subjects who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is defined by the local standard of care
International normalized ratio (INR) < 1.5
“International normalized ratio” or INR must be =< 1.5
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
Ongoing treatment with warfarin unless the international normalized ratio (INR) is well controlled and below 4
Patients must be appropriate candidates for RFA, with an international normalized ratio of 1.5
INR > 1.5
International normalized ratio (INR) =< 1.5 x upper limit of normal unless patient is receiving anticoagulants; if patient is on anticoagulation therapy, levels should be within therapeutic range
Patient has acceptable coagulation status; for patients not receiving anticoagulation: international normalized ratio of a measure of prothrombin time =< 1.3
International normalized ratio (INR) =< 1.5
For patients not receiving anticoagulation: international normalized ratio of a measure of prothrombin time (international normalized ratio [INR]) =< 1.3
Patients must have an International Normalized Ratio (INR) < 1.5 and a partial thromboplastin time (PTT) no greater than upper limits of normal within 1 week prior to randomization
International Normalized Ratio (INR) < 1.5 and aPTT within 1.1 x ULN
International normalized ratio (INR) < 1.5
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN\r\n* Unless the patient is on therapeutic anticoagulation
International normalized ratio (INR) >1.5x ULN
International normalized ratio (INR) >2.3 or prothrombin time (PT) >6 seconds above control
Adequate coagulation parameters, defined as international normalization ratio (INR) ?
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
TPI 287 may interfere with coumadin dosing and patients who are taking this combination will require monitoring of their PT, PTT and international normalized ratio (INR).
International normalized ratio (INR) greater than 1.3
International Normalized Ratio (INR) ?1.7
Vitamin K antagonist therapy and an international normalized ratio >1.3 on the day of surgery.
Partial thromboplastin time (PTT) must be =< 1.5 X upper normal limit of institution's normal range and international normalized ratio (INR) < 1.5; subjects on anticoagulant (such as Coumadin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigator
An abnormal INR (international normalized ratio of greater than 1.3), if repeatable and refractory to correction by routine methods
International normalized ratio (INR) >= 1.5
Coagulation: International Normalized Ratio (INR) ? 1.2
Activated partial thromboplastin time (APTT) must not exceed 32.5 seconds (normal range 21.8-31.5 seconds); international normalized ratio (INR) must not exceed 1.30 (normal range 0.87-1.18)
International normalized ratio (INR) </=1.5 times ULN
International Normalized Ratio (INR) and activated partial thromboplastin time [PTT] ? 1.5×ULN, if not therapeutically anticoagulated.
Has adequate blood clotting function, defined as: International normalized ratio and activated partial thromboplastin time <= 1.5 X ULN
International normalized ratio (INR) < 1.5 or patient off Coumadin at the time of ablation
International normalized ratio (INR) < 1.5; if on anticoagulation: INR is required to be between 2 and 3
International normalized ratio (INR) and partial thromboplastin time (PTT) </=1.5 times ULN (upper limit of normal)
INR ? 1,5
Known coagulopathy (international normalized ratio [INR] > 1.5, platelets < 75 K)
International normalized ratio (INR) < 1.5 × ULN
Prothrombin time (PT) with international normalized ratio (INR) ?1.5
International normalized ratio (INR) > 2.5 and/or
International normalized ratio (INR) less than or equal to (?) 1.6 (unless receiving anticoagulation therapy)
International normalized ratio (INR) =< 2
International normalized ratio (INR) < 1.3 (or ? 3.0 if on therapeutic anticoagulation)
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) < 1.3 (or < 3 on anticoagulants)
International normalized ratio (INR) =< 1.5 x ULN; patients receiving anti-coagulation therapy are permitted as long as they have a stable INR =< 3.0
Prothrombin time/international normalized ratio (PT INR) < 1.4
International normalized ratio (INR) =< 1.5 or
International normalized ratio (INR) < 1.5 or a prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits; patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate; for patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable
Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolism)
International normalized ratio (INR) =< 1.2 X upper limit of normal (ULN)
International normalized ratio (INR) =< 1.3 (or =< 3 on anticoagulants)
The participant either has adequate coagulation function as defined by international normalized ratio (INR) ? 1.5 and partial thromboplastin time (PTT) no more than 5 seconds above the ULN, or is on a stable dose of anticoagulant
Prothrombin time International Normalized Ratio (INR) > 1.5
International normalized ratio (INR) < 1.5
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 2.0
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) < 1.5 x ULN unless patients are receiving anti-coagulation therapy; patients receiving anti-coagulation therapy with an agent such as warfarin or heparin are allowed to participate if INR =< 3.0
International normalized ratio (INR) > 2
Severe hepatic dysfunction accompanied by coagulopathy definition:\r\n* Known liver disease AND\r\n* International normalized ratio (INR) > 1.5 (except for patients on anticoagulants) AND\r\n* Platelet count < 100,000/uL without other obvious cause
Prothrombin time (PT) and/or international normalized ratio (INR) ? 1.3 × the upper limit of normal (ULN)
Within 30 days of surgery: International normalized ratio (INR) =< 1.5
Patients with history of severe liver disease, defined as and confirmed by international normalized ratio (INR) 1.5 or greater per institutional laboratory.
International normalized ratio (INR) < 1.3 (or < 3 if on anticoagulant therapy).
International normalized ratio (INR) =< 1.5 (corrected if needed)
Currently on warfarin with an international normalized ratio (INR) > 1.4 or clopidogrel that cannot be discontinued 7 days prior to surgery
International normalized ratio (INR) > 1.5
International normalized ratio (INR) =< 1.8 times institutional upper limit of normal
Prothrombin time (PT) such that international normalized ratio (INR) is < 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin)
Abnormal coagulation parameters (international normalized ratio [INR] > 1.5 not on Coumadin, or platelet count < 100,000)
Coagulopathy (international normalized ratio [INR] > 2, platelets < 50,000)
International normalized ratio (INR)/ partial thromboplastin time (PTT) =< 1.5 x ULN
Obtained =< 30 days prior to randomization: International normalized ratio (INR) =< 1.6 (if not taking anticoagulant therapy)
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) </= 2 x ULN
An international normalized ratio (INR) =< 1.5 (patients who are therapeutically anticoagulated for unrelated medical conditions such as atrial fibrillation and whose antithrombotic treatment can be withheld for operation will be eligible)
International Normalized Ratio (INR) ?1.5 and a partial thromboplastin time (PTT) ?5 seconds above the ULN.
International normalized ratio (INR) =< 1.5
Patients with international normalized ratio (INR) > 1.5
International normalized ratio (INR) =< 2
An international normalized ratio (INR) > 1.6, or a partial thromboplastin time (PTT) > 40 seconds
Minocycline trial only: patients who are under treatment of warfarin with international normalized ratio (INR) > 1.5
INR (International Normalized Ratio) <1.5 within 6 weeks screening
International normalized ratio (INR) =< 1.5 (within 30 days of surgery)
Partial thromboplastin time (PTT) greater than 50 seconds (sec) or international normalized ratio (INR) greater than 2.0
International normalized ratio (INR) > 1.4 and activated partial thromboplastin time (aPTT) > 3 seconds above the upper limit of normal for age, within 1 week prior to enrollment.
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) or prothrombin time (PT) within normal institutional limits
Subjects with coagulopathies, including thrombocytopenia with platelet count < 75,000, international normalized ratio (INR) > 1.5 and partial thromboplastin time > 50 sec
International normalized ratio (INR) =< 2
International Normalized Ratio (INR) and activated Partial Thromboplastin Time [PTT] within normal institutional limits
International normalized ratio (INR) and activated thromboplastin time within normal institutional limits
International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 1.3
Patients should have international normalized ratio (INR) =< 1.4 and prothrombin time (PT) =< 40 seconds (unless due to lupus anticoagulant); in patients not meeting these parameters, clearance by hematology will be required prior to undergoing a biopsy
International normalized ratio (INR) < 1.5 \r\n* For patients on Coumadin general clinical guidelines for interventional radiology (IR) ablation will be followed
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 X upper limit of normal (ULN) (evaluated within 28 days of randomization); subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
Coagulopathy with international normalized ratio (INR) > 2.0 or
Severe coagulopathy (international normalized ratio [INR] > 1.8) or
Complete blood count (CBC), chemistry panel (CMP) and coagulation panel (prothrombin time [PT] & international normalized ratio [INR]) no greater than 4 weeks prior to registration
Adequate blood coagulation as evidenced by an International Normalized Ratio (INR) ?1.5.
Low-density lipoprotein (LDL) question for lung surgery do we need an international normalized ratio (INR) < 1.6
International normalized ratio (INR) < 1.3 (or < 3 if on warfarin or other anticoagulants) at the screening visit
International Normalized Ratio (INR) < 1.5 (except if patient is on oral anticoagulation therapy).
International Normalized Ratio (INR) >1.5 x ULN
Adequate blood clotting as defined by international normalized ratio (INR) and activated partial thromboplastin time (aPTT) ? 1.5 times ULN (patients on anticoagulation with an agent such as warfarin or heparin or rivoraxaban will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists). For patients on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre-dose, as defined by the local standard of care
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ?1.5.
